Literature DB >> 15126306

Quantitative PCR analysis of mitochondrial DNA content in patients with mitochondrial disease.

Ren-Kui Bai1, Cherng-Lih Perng, Chang-Hung Hsu, Lee-Jun C Wong.   

Abstract

Molecular diagnosis of mitochondrial DNA disorder is usually focused on point mutations and large deletions. In the absence of detectable mtDNA mutations, abnormal amounts of mtDNA, either depletion or elevation, can be indicative of mitochondrial dysfunction. The amount of mitochondrial DNA (mtDNA), however, varies among individuals of different ages and among different tissues within the same individual. To establish a range of mtDNA levels, we analyzed 300 muscle and 200 blood specimens from patients suspected of having a mitochondrial disorder by real-time quantitative polymerase chain reaction (PCR) method. Copy numbers were calculated from the standard curve and threshold cycle number using TaqMan probes; 6FAM 5'TTACCGGGCTCTGCCATCT3'-TAMRA and VIC-5'AGCAATAACAGGTCTGTGATG3'-TAMRA for mtDNA and 18S rRNA gene (nDNA), respectively. The copy number ratio of mtDNA to nDNA was used as a measure of mtDNA content in each specimen. The mtDNA content in muscle increases steadily from birth to about 5 years of age; thereafter, it stays about the same. On the contrary, the mtDNA content in blood decreases with age. The amount of mtDNA in skeletal muscle is about 5-20 times higher than that in blood. About 7% of patients had mtDNA levels in muscle below 20% of the mean of the age-matched group, and about 10% of patients had muscle mtDNA levels 2- to 16-fold higher than the mean of the age-matched group. Patients with abnormal levels of mtDNA, either depletion or proliferation, had significant clinical manifestations characteristic of mitochondrial disease in addition to abnormal respiratory enzymes and mitochondrial cytopathies. Cardiomyopathy, lactic acidosis, abnormal brain MRI findings, hypotonia, developmental delay, seizures, and failure to thrive are general clinical pictures of patients with mtDNA depletion. The average age of patients with mtDNA depletion is 4.1 years, compared to 23.6 years in patients with mtDNA proliferation. Mutations in nuclear genes involved in mtDNA synthesis and deoxynucleotide pools are probably the cause of mtDNA depletion. Our results demonstrate that real time quantitative PCR is a valuable tool for molecular screening of mitochondrial diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15126306     DOI: 10.1007/978-3-662-41088-2_29

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  41 in total

1.  A novel interaction between DNA ligase III and DNA polymerase gamma plays an essential role in mitochondrial DNA stability.

Authors:  Ananya De; Colin Campbell
Journal:  Biochem J       Date:  2007-02-15       Impact factor: 3.857

2.  Hypoxia-inducible factors have distinct and stage-specific roles during reprogramming of human cells to pluripotency.

Authors:  Julie Mathieu; Wenyu Zhou; Yalan Xing; Henrik Sperber; Amy Ferreccio; Zsuzsa Agoston; Kavitha T Kuppusamy; Randall T Moon; Hannele Ruohola-Baker
Journal:  Cell Stem Cell       Date:  2014-03-20       Impact factor: 24.633

3.  MGB probe assay for rapid detection of mtDNA11778 mutation in the Chinese LHON patients by real-time PCR.

Authors:  Jian-yong Wang; Yang-shun Gu; Jing Wang; Yi Tong; Ying Wang; Jun-bing Shao; Ming Qi
Journal:  J Zhejiang Univ Sci B       Date:  2008-08       Impact factor: 3.066

4.  Quantitative Analysis of mtDNA Content in Formalin-Fixed Paraffin-Embedded Muscle Tissue.

Authors:  Aida Font; Frederic Tort; Aleix Navarro-Sastre; Victòria Cusí; Judit García-Villoria; Paz Briones; Antonia Ribes
Journal:  JIMD Rep       Date:  2011-06-22

5.  Influenza M2 protein regulates MAVS-mediated signaling pathway through interacting with MAVS and increasing ROS production.

Authors:  Ruifang Wang; Yinxing Zhu; Xian Lin; Chenwei Ren; Jiachang Zhao; Fangfang Wang; Xiaochen Gao; Rong Xiao; Lianzhong Zhao; Huanchun Chen; Meilin Jin; Wenjun Ma; Hongbo Zhou
Journal:  Autophagy       Date:  2019-02-20       Impact factor: 16.016

6.  Depression, telomeres and mitochondrial DNA: between- and within-person associations from a 10-year longitudinal study.

Authors:  J E Verhoeven; D Révész; M Picard; E E Epel; O M Wolkowitz; K A Matthews; B W J H Penninx; E Puterman
Journal:  Mol Psychiatry       Date:  2017-03-28       Impact factor: 15.992

7.  Detection of common disease-causing mutations in mitochondrial DNA (mitochondrial encephalomyopathy, lactic acidosis with stroke-like episodes MTTL1 3243 A>G and myoclonic epilepsy associated with ragged-red fibers MTTK 8344A>G) by real-time polymerase chain reaction.

Authors:  Hongxin Fan; Chris Civalier; Jessica K Booker; Margaret L Gulley; Thomas W Prior; Rosann A Farber
Journal:  J Mol Diagn       Date:  2006-05       Impact factor: 5.568

8.  A new link to mitochondrial impairment in tauopathies.

Authors:  Kathrin L Schulz; Anne Eckert; Virginie Rhein; Sören Mai; Winfried Haase; Andreas S Reichert; Marina Jendrach; Walter E Müller; Kristina Leuner
Journal:  Mol Neurobiol       Date:  2012-07-31       Impact factor: 5.590

9.  Loss of the antioxidant enzyme CuZnSOD (Sod1) mimics an age-related increase in absolute mitochondrial DNA copy number in the skeletal muscle.

Authors:  Dustin R Masser; Nicholas W Clark; Holly Van Remmen; Willard M Freeman
Journal:  Age (Dordr)       Date:  2016-07-21

10.  Molecular basis of infantile reversible cytochrome c oxidase deficiency myopathy.

Authors:  Rita Horvath; John P Kemp; Helen A L Tuppen; Gavin Hudson; Anders Oldfors; Suely K N Marie; Ali-Reza Moslemi; Serenella Servidei; Elisabeth Holme; Sara Shanske; Gittan Kollberg; Parul Jayakar; Angela Pyle; Harold M Marks; Elke Holinski-Feder; Mena Scavina; Maggie C Walter; Jorida Coku; Andrea Günther-Scholz; Paul M Smith; Robert McFarland; Zofia M A Chrzanowska-Lightowlers; Robert N Lightowlers; Michio Hirano; Hanns Lochmüller; Robert W Taylor; Patrick F Chinnery; Mar Tulinius; Salvatore DiMauro
Journal:  Brain       Date:  2009-08-31       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.